Phase 1 N=29 Determining How Quickly Progesterone Slows LH Pulse Frequency
Normal · PCOS
Primary: LH Pulse Frequency — 1.31; 0.91; 1.33; 1.19 pulses/hour
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)
Human Immunodeficiency Virus
Primary: Change From Baseline in Plasma HIV-1 Ribonucleic Acid (RNA) — -1.38; -1.40; -0.80 HIV-1 RNA copies/mL
Phase 1 N=17 A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
Negative Symptoms in Schizophrenia
Primary: Extrapyramidal Symptoms Assessed by Abnormal Involuntary Movement Scale (AIMS) - Change From Baseline in AIMS Component Movement — 0.0 score on a scale
Phase 1 N=25 Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant
Cough · Healthy
Primary: Part 1: Area Under the Concentration-time Curve From Time Zero to Infinity (AUC-inf) of Camlipixant — 4886.66; 10642.07 Hours*nanograms per milliliter
Phase 1 N=12 A Study of 123I-CMICE-013 Radiopharmaceutical in Healthy Volunteers
Coronary Artery Disease
Primary: Biodistribution of the 123I-CMICE-013 Within the Lungs — 8.4; 7.1; 7.1; 6.2 percentage of total injected dose
Phase 1 N=143 A Study to Assess the Safety and Immune Response to Env-C DNA and Protein Vaccines in Kenya
HIV Infections
Primary: Number of Solicited Local Events Post Vaccination 1 by Priming Dose Group (Outcome 1) — 23; 27; 25; 10 Participants
Phase 1 N=54 A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics (PD) of GSK3888130B in Healthy Participants
Multiple Sclerosis · Colitis, Ulcerative
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 8; 3; 2; 6 Participants
Phase 1 N=8 Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women
Transgender Health · Gender Dysphoria · Transgender Women
Primary: Doravirine Area Under the Plasma Concentration Versus Time Curve From 0 Hours to Infinity (AUC0-∞) — 17798.14; 18413.21 hr*ng/mL
Phase 1 N=110 A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer
Gastrointestinal Neoplasms · Cholangiocarcinoma · Pancreatic Neoplasms
Primary: Maximum Tolerated Dose (MTD) of BI 905711 in Phase 1a — NA milligram / kilogram (mg/kg)
Phase 1 N=20 Phase I Open Label BCG Clinical Trial Assessing TB Drugs and Vaccines
Tuberculosis
Primary: Assess Viable BCG Bacteria From Intradermal Challenge Site From Culture. — 20,440; 80; 5; 10,673 CFU
Phase 1 N=15 A Study to Evaluate Vonoprazan Concentrations in Breast Milk of Healthy Lactating Women Receiving Vonoprazan 20 mg Once Daily or Vonoprazan 20 mg Twice Daily
Erosive Esophagitis · Heartburn · Symptomatic Nonerosive Gasroesophageal Reflux Disease
Primary: Area Under Drug Concentration-time Curve From Time 0 to 24 Hours (AUC0-24) Following the Morning Dose of Vonoprazan in Breast Milk — 179; 317 ng•h/mL
Phase 1 N=6 Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK
Myoclonus Epilepsies, Progressive
Primary: Number of Participants With Treatment-Related Adverse Events After Single Dose Treatment of AUT00201 Compared to Placebo — 5; 5 Participants
Phase 1 N=83 This Study in Healthy Men Tests How Different Doses of BI 1358894 Are Taken up in the Body and How Well They Are Tolerated. The Study Also Looks at How Food Influences the Amount of BI 1358894 in the Blood
Healthy
Primary: Percentage of Subjects With Drug- Related Adverse Event — 0.0; 16.7; 50.0; 0.0 Percentage
Phase 1 N=20 QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803
Healthy
Primary: PK Profile - Half-life (t½) — 1.07; 0.55; 1.02; 0.68 Days
Phase 1 N=8 A Sub Study to Evaluate the Study Medication (Etrasimod) Using Wearable Sensors in Healthy Participants
Healthy Participants
Primary: Area Under the Serum Concentration-Time Profile From Time Zero to 24 Hours (AUC0-24) of Etrasimod: Tasso PK Sampling — 666.4; 745.5 Nanogram*hour per milliliter…